Burgeon Bio Completes Nearly RMB 100 Million Series A Financing to Build a Global Leading One-Stop Organoid Model Platform

VCBeat (WeChat ID: vcbeat) has learned that bioGenous (Suzhou) Co., Ltd. (hereinafter referred to as “bioGenous”) recently announced the completion of its Series A financing round, raising nearly RMB 100 million. The round was led by SDIC Investment Promotion, with existing shareholder MARATHON VENTURE PARTNERS participating in oversubscribed follow-on investment. With this funding, bioGenous will further enhance its globally leading technological platform for organoid CDMO and CRO services, accelerate the construction and operation of its commercial-scale production facility, and expand into overseas markets.

bioGenous is deeply committed to foundational technological innovation in the organoid industry, boasting globally leading capabilities in organoid model construction. The company is dedicated to providing standardized and modular organoid products and technical support for biomedical scientific research, drug development, and clinical precision medicine. Its scientific team has established several cutting-edge platforms, including the world’s first human-derived organoid model for SARS-CoV-2 infection, models for tumorigenesis such as medulloblastoma, new drug development platforms, the world’s first fully automated organoid biobanking and high-throughput drug screening system, and innovative organoid models based on the analysis of tissue and tumor microenvironments. Additionally, bioGenous offers a comprehensive portfolio of reagents and kits covering multi-lineage and multi-cancer type organoids, along with end-to-end CDMO and CRO technical service systems.

The company currently operates a 3,000 m² R&D and production facility, with three major R&D and operational centers established in Suzhou, Shanghai, and Dezhou. In 2023, its 10,000 m² large-scale industrialization base will also be fully operational. At that time, bioGenous will have four GMP Grade B production lines for reagents and kits, six GMP Grade C production lines for organoid technology services, and dozens of cleanrooms. To date, the company has served more than 300 new drug R&D enterprises, Grade A tertiary hospitals, and research institutes, providing users with products and services such as automated organoid equipment, multi-tissue full-process kits, technical solutions for organoid culture and biobank construction, and subsystems for organoid-based drug development and precision medicine.

Following this round of financing, bioGenous will continue to strengthen its platform capabilities in multi-lineage, multi-cancer organoid construction, genetic manipulation, drug discovery and efficacy evaluation, and patient-derived xenograft (PDX) models. The company aims to comprehensively enhance production capacity and lead the revolution in biomedical modeling across multiple fields. This funding round will also support bioGenous in expanding into overseas markets, accelerating the global deployment of its end-to-end products and services based on proprietary organoid technologies, and promoting the pharmaceutical industry’s adoption of this emerging organoid technology.

bioGenous Founding Teamstated: “We extend our sincere gratitude to SDIC Merchants, MARATHON VENTURE PARTNERS, and other new and existing shareholders for their trust and support. The application value of organoid technology has been highly recognized in both basic scientific research and the pharmaceutical industry. Leveraging its unique advantage of high biomimicry, it holds broad application prospects in new drug development, precision medicine, and regenerative medicine. Building on its existing platform and services, bioGenous will further focus on breakthroughs in cutting-edge organoid technologies, development of innovative application models, and the construction of high-standard, high-capacity pipelines. By establishing a comprehensive organoid service ecosystem, we aim to accelerate advancements in life science research and the pharmaceutical industry.”

SDIC Investment Promotion Life Sciences Team“It stated: ‘As a revolutionary frontier technology in the biomedical sector, organoid technology boasts broad development prospects and significant industrial demand. SDIC Investment Management highly recognizes the company team’s profound professional expertise in the field of organoids. It will fully leverage the extensive biomedical industry ecosystem resources accumulated by the fund over the long term to join hands with bioGenous in jointly promoting technological innovation and industrial application of organoid technology, thereby accelerating innovation in China’s biomedical industry.’”

SDIC Merchants focuses on investments in the advanced manufacturing industry, emphasizing technological innovation and the value of outstanding entrepreneurs and teams. It prioritizes investments in fields such as intelligent manufacturing, new energy smart vehicles, life sciences, and information and communications technology (ICT), committing to promoting the green, digital, and service-oriented development of the manufacturing sector. The team manages a cumulative asset scale exceeding RMB 100 billion, with investors including financial institutions, the National Social Security Fund, and state-owned and private capital.

MARATHON VENTURE PARTNERS focuses on early-stage venture capital investments in digital health technologies. It is deeply committed to building three core infrastructures: efficient patient access, innovative payment solutions, and operational efficiency enhancement. The firm strategically invests in medical device and equipment companies with core technologies and innovative business models, as well as in precision diagnostics, mobile healthcare services, and health insurance technology companies. Its assets under management exceed RMB 3 billion. Recent portfolio companies include Shukun Technology, a leader in AI-based medical imaging; Medbanks Health, a pioneer in innovative healthcare payment solutions; Realint Technology, a dental 3D printing equipment manufacturer; Baideng Medical, a B2B distribution platform for medical devices; and Lenuo Medical, an enterprise specializing in interventional devices for ENT (ear, nose, and throat) applications.

bioGenous was established in March 2021, completed group restructuring in September 2022, and is headquartered in Suzhou Industrial Park. The company is dedicated to providing standardized organoid products and integrated technical services, covering three key application scenarios: basic research, precision medicine, and drug development. Upholding the vision of “Leading Pharmaceutical Innovation, Sharing Model Value,” bioGenous leverages world-class R&D talent as its core and adheres to its mission of building a “Globally Leading Organoid Model Platform.” By committing to high-quality and efficient services, the company aims to substantially enhance clients’ efficiency in new drug development and their capabilities in basic research, thereby accelerating public access to better medicines.